Traders Sell Vertex Pharmaceuticals (VRTX) on Strength on Insider Selling

Traders sold shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on strength during trading hours on Friday following insider selling activity. $63.69 million flowed into the stock on the tick-up and $121.48 million flowed out of the stock on the tick-down, for a money net flow of $57.79 million out of the stock. Of all companies tracked, Vertex Pharmaceuticals had the 0th highest net out-flow for the day. Vertex Pharmaceuticals traded up $0.29 for the day and closed at $180.55Specifically, CFO Thomas Graney sold 1,076 shares of the company’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $193.24, for a total value of $207,926.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David Altshuler sold 4,126 shares of the company’s stock in a transaction on Monday, November 5th. The shares were sold at an average price of $173.51, for a total transaction of $715,902.26. Following the completion of the sale, the executive vice president now owns 40,909 shares of the company’s stock, valued at approximately $7,098,120.59. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,550 shares of company stock valued at $5,482,235. 1.80% of the stock is owned by insiders.

Several analysts recently commented on VRTX shares. Zacks Investment Research downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, September 11th. Raymond James started coverage on shares of Vertex Pharmaceuticals in a research report on Tuesday, October 2nd. They set a “buy” rating for the company. Stifel Nicolaus upped their price objective on shares of Vertex Pharmaceuticals from $182.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, August 7th. Citigroup upped their price objective on shares of Vertex Pharmaceuticals from $203.00 to $206.00 and gave the stock a “buy” rating in a research report on Monday, July 30th. Finally, HC Wainwright upgraded shares of Vertex Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $220.00 price objective for the company in a research report on Friday, October 26th. Three research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $202.14.

The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.59 and a current ratio of 3.71. The company has a market capitalization of $44.78 billion, a price-to-earnings ratio of 225.69, a price-to-earnings-growth ratio of 1.74 and a beta of 1.61.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, October 24th. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.02 by $0.07. Vertex Pharmaceuticals had a net margin of 22.87% and a return on equity of 22.92%. The business had revenue of $784.54 million for the quarter, compared to analysts’ expectations of $782.95 million. During the same period in the prior year, the company posted $0.53 EPS. Research analysts predict that Vertex Pharmaceuticals Incorporated will post 2.55 EPS for the current year.

Several large investors have recently bought and sold shares of VRTX. FMR LLC grew its stake in Vertex Pharmaceuticals by 10.5% in the 3rd quarter. FMR LLC now owns 18,071,478 shares of the pharmaceutical company’s stock valued at $3,483,097,000 after acquiring an additional 1,714,071 shares during the last quarter. Renaissance Technologies LLC grew its stake in Vertex Pharmaceuticals by 42.1% in the 2nd quarter. Renaissance Technologies LLC now owns 4,050,617 shares of the pharmaceutical company’s stock valued at $688,443,000 after acquiring an additional 1,199,700 shares during the last quarter. Jennison Associates LLC grew its stake in Vertex Pharmaceuticals by 22.5% in the 3rd quarter. Jennison Associates LLC now owns 6,202,493 shares of the pharmaceutical company’s stock valued at $1,195,468,000 after acquiring an additional 1,139,486 shares during the last quarter. American Century Companies Inc. grew its stake in Vertex Pharmaceuticals by 357.5% in the 2nd quarter. American Century Companies Inc. now owns 1,125,428 shares of the pharmaceutical company’s stock valued at $191,278,000 after acquiring an additional 879,411 shares during the last quarter. Finally, Standard Life Aberdeen plc grew its stake in Vertex Pharmaceuticals by 238.9% in the 2nd quarter. Standard Life Aberdeen plc now owns 1,144,913 shares of the pharmaceutical company’s stock valued at $194,646,000 after acquiring an additional 807,086 shares during the last quarter. 93.51% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This news story was first reported by WKRB News and is the property of of WKRB News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.wkrb13.com/2018/11/10/traders-sell-vertex-pharmaceuticals-vrtx-on-strength-on-insider-selling.html.

Vertex Pharmaceuticals Company Profile (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

See Also: What is a capital gain?

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply